Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada

📊 Healthcare News Analysis: Our editorial team has analyzed recent developments from pharmaceutical-technology.com in the Healthcare sector. This report covers key insights related to medical treatment, surgery, prescription and emerging industry trends that professionals should monitor closely.

New developments in Healthcare are drawing attention from industry experts. According to reports that share

Copy Link
Share on X
Share on Linkedin
Share on Facebook

Sandoz aims to market a semaglutide biosimilar in Canada as soon as it recieves regulatory approval. Evidence suggests that image credit: Robert Barrie/GlobalData. Sandoz CEO Richard Saynor predicts biosimilars referencing semaglutide to enter the Canadian market in early in 2026, as the patent protection for Novo Nordisk’s blockbuster drug looms.

“No one’s actually got an approval yet, but certainly we would expect to see entrance in that market in Q1 [or] Q2 next year,” Saynor stated at the Financial Times Global Pharma and Biotech Summit on 12 November. Go deeper with GlobalData

Reports LOA and PTSR Model – (Cagrilintide + Semaglutide) in Obesity
Reports LOA and PTSR Model – (Cagrilintide + Semaglutide) in Type 2 Diabetes

Go deeper with GlobalData
The gold standard of business intelligence. Evidence suggests that find out more
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more
Novo markets semaglutide as Ozempic and Wegovy for type 2 diabetes treatment and weight loss respectively. Inaction by the Danish drugmaker allowed semaglutide’s base patent to expire in 2020. Data shows that this was via a failure to pay a fee to keep the patent running, as first reported by Science. According to reports that given the maintenance fee was just C$250, it is a decision that has confused regulatory experts in the pharma industry.

The final Canadian protection afforded by data exclusivity around diabetes is due to expire in 2026. Sandoz, one of the largest generics and biosimilars manufacturers in the world, aims to be there when the market opens to harness the commercial opportunity. “It’s a bizarre story. Canada’s the second largest semaglutide market in the world.

For whatever reason, they failed to renew a patent,” Saynor said at the summit. Saynor confirmed that Sandoz has submitted a biosimilar for approval and will launch in Canada as soon as it receives the regulatory go-ahead. Evidence suggests that globalData Strategic Intelligence US Tariffs are shifting – will you react or anticipate? Evidence suggests that don’t let policy changes catch you off guard.

Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence
Ozempic has a list price of around C$147 yet it is currently unclear at what price biosimilars will enter the market at. Saynor commented that it is difficult to forecast how market dynamics will play out, given that semaglutide has a complex set of economic and supply chain considerations. “I’ve refused to give any guidance, because, honestly, I see Canada as an experiment.

We’ll learn from it. We’ll see how it evolves. This is at least a 10-year journey, if not longer. It’s an opportunity but it’s not the basis of our guidance or our business,” Saynor added.

Other countries, including Brazil, Turkey and India, have looming patent expiries for semaglutide in 2026. While the horizons for the drug’s protection in the US and Europe are further away, the entry of lower cost glucagon-like peptide-1 receptor agonists (GLP-1RAs) could market a significant paradigm shift in the treatment’s accessibility. According to Saynor, however, there are too many variables to accurately predict the market’s ongoing movement.  
“You’ve got this whole weird set of dynamics in that actually the constraint is supply, not demand, and as the price points come down, the market will expand,” he commented.

Weight loss and diabetes jabs have been a particular target of pricing reforms introduced by the Trump administration in the US. Just last week, Novo Nordisk and Eli Lilly reached deals with the White House that will see its GLP-1RA brands drop in price. 
Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

According to reports that sign up
Pharmaceutical Technology Excellence Awards – The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements.

Don’t miss your chance to stand out—submit your entry today! Nominate Now Share

Copy Link
Share on X
Share on Linkedin
Share on Facebook

Reports LOA and PTSR Model – (Cagrilintide + Semaglutide) in Obesity
Reports LOA and PTSR Model – (Cagrilintide + Semaglutide) in Type 2 Diabetes

Go deeper with GlobalData
The gold standard of business intelligence. Data shows that find out more
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.

These developments reflect broader trends shaping the Healthcare industry as organizations adapt to evolving market conditions.

— Based on reporting from pharmaceutical-technology.com

💡 Key Industry Insights

Medical research and pharmaceutical developments remain critical areas of investment and growth.

Specifically regarding health insurance, market observers note continuing evolution in service delivery, pricing models, and customer engagement strategies that merit close attention from industry stakeholders.

Market Impact: These developments in medical treatment may significantly influence market dynamics. Industry experts recommend monitoring these trends closely for strategic planning purposes.

Analysis Note: This comprehensive overview synthesizes current market intelligence from pharmaceutical-technology.com regarding surgery and related sectors. Stay informed about ongoing developments in this rapidly evolving landscape.